Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer

Plasma genotyping identifies potentially actionable mutations at variable mutant allele frequencies, often admixed with multiple subclonal variants, highlighting the need for their clinical and functional validation. We prospectively monitored plasma genotypes in 143 women with endocrine-resistant m...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:NPJ Precis Oncol
Autors principals: Medford, Arielle J., Dubash, Taronish D., Juric, Dejan, Spring, Laura, Niemierko, Andrzej, Vidula, Neelima, Peppercorn, Jeffrey, Isakoff, Steven, Reeves, Brittany A., LiCausi, Joseph A., Wesley, Benjamin, Malvarosa, Giuliana, Yuen, Megan, Wittner, Ben S., Lawrence, Michael S., Iafrate, A. John, Ellisen, Leif, Moy, Beverly, Toner, Mehmet, Maheswaran, Shyamala, Haber, Daniel A., Bardia, Aditya
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6635494/
https://ncbi.nlm.nih.gov/pubmed/31341951
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41698-019-0090-5
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars